Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 14/20 | 0.62 |
| ▸ | TACR2 | P21452 | 10/20 | 0.62 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.58 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.48 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.45 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1580933 | 1.00 | TACR3 (0.62) | TACR3TACR2OPRM1CYP2C9NTRK1 | |
| SCHEMBL1580919 | 0.87 | TACR3 (0.67) | TACR3TACR2OPRM1CYP2C9NTRK1 | |
| SCHEMBL1581337 | 0.86 | TACR3 (0.66) | TACR3TACR2OPRM1CYP2C9TRPV4 | |
| SCHEMBL5425877 | 0.85 | CYP2C9 (0.75) | TACR3TACR2OPRM1CYP2C9NTRK1 | |
| SCHEMBL3326515 | 0.83 | TACR3 (0.71) | TACR3TACR2CYP2C9 | |
| SCHEMBL1581353 | 0.83 | TACR3 (0.71) | TACR3TACR2CYP2C9 | |
| SCHEMBL1581422 | 0.82 | TACR3 (0.63) | TACR3TACR2OPRM1CYP2C9NTRK1 | |
| SCHEMBL8193060 | 0.82 | TACR3 (0.63) | TACR3TACR2OPRM1CYP2C9NTRK1 | |
| SCHEMBL5420737 | 0.82 | TACR3 (0.71) | TACR3TACR2OPRM1CYP2C9NTRK1 | |
| SCHEMBL3322299 | 0.81 | TACR3 (0.53) | TACR3TACR2OPRM1CYP2C9TRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120850-A1 | Quinoline Derivatives, Pharmaceutical Compositions Comprising Them, and Their Use in Treating Central Nervous System and Peripheral Diseases | ASTRAZENECA AB (SE) | 2010-05-13 | — | — | US | disclosed |
| US-20100120850-A1 | Quinoline Derivatives, Pharmaceutical Compositions Comprising Them, and Their Use in Treating Central Nervous System and Peripheral Diseases | ASTRAZENECA AB (SE) | 2010-05-13 | — | — | US | disclosed |
| WO-2008115140-A1 | QUINOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM, AND THEIR USE IN TREATING CENTRAL NERVOUS SYSTEM AND PERIPHERAL DISEASES | ASTRAZENECA AB (SE) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120850-A1 | Quinoline Derivatives, Pharmaceutical Compositions Comprising Them, and Their Use in Treating Central Nervous System and Peripheral Diseases | PMP22, RECQL, ACHE | TACR3 531/4885TACR2 1434/4885OPRM1 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.